HCV GT 1b-PI-luc, a bi-cistronic replicon and cured Huh7 cells (Huh-Lunet) were 208 obtained from ReBLikon (Mainz, Germany) (12). To clone the NS3 protease gene from 209 patient isolates, two unique restriction sites (ClaI and AscI) were created in the 1b-PI-luc 210 construct (17). 211 PCR products generated for NS3 sequencing were used as template to generate gene 212 cassettes encoding cloning sites at both ends. For GT 1b samples, the protease gene was 213 amplified using the forward primer 1b PCR NS3-4A F2 (5'-ATTAGTCAATCGATA 214 CCATGGCGCCYATCACGGCCTACTCCCAACAGACGCG-3') and the reverse 215 ACCGGRGACCGCATRGTRGTTCCCAT-3'). For GT 1a samples, the forward primer 217 1a PCR NS3-4A F2 (5'-ATTAGTCAATCGATACCATGGCGCCCATCACGGCGT 218 ACGCCCAGCAGAC-3') and the reverse primer 1a PCR Prot R2 (E1202G) (5'-ATA 219 TGCTCAGGCGCGCCGTTGTCCGTGAACACCGGGGACCTCATGGTTGTCCCT 220 AGG-3') were used. 
Antiviral Response to GS-9451 262
The samples analyzed in this phase 1 study were obtained from 25 GT 1a patients and 7 263 GT 1b patients who were dosed with GS-9451 for 3 days as well as 8 patients (7 GT 1a 264 and 1 GT 1b) who received placebo for 3 days. The GS-9451 60 mg QD dose for 3 days 265 resulted in a mean maximal HCV RNA reduction of -0.91 log 10 IU/mL in HCV GT 1a 266 patients (Table 1) . Mean maximal reductions in HCV RNA were -3.16 log 10 IU/mL for 267 200 mg QD GT 1a, -3.26 log 10 IU/mL for 200 mg QD GT 1b and -3.77 log 10 IU/mL for 268 400mg QD GT 1a compared to -0.2 log 10 IU/mL reduction for placebo patients. 269
Comparison of the maximum viral reduction between the two subtypes at 200 mg QD 270 dose showed that there was not a statistically significant difference(p = 0.7). 271
272

Population Sequencing Analysis 273
Population sequencing of HCV NS3 did not detect any of the previously identified HCV 274 PI-resistance mutation at positions 155, 156 and 168 in any of the patients at baseline. 275
Drug resistance mutations were also not detected in patients receiving placebo or 60 mg 276 of GS-9451 for 3 days by population sequencing (Table 2) (Table 2 ). For these GT 1b patients, D168E/V/G were no longer detected 284 by population sequencing in any patient at Day 14 or the Week 12 and Week 24 follow-285 up time points (Table 3) . 286
287
Other Substitutions in the NS3 Protease Gene (AA 1-181) 288
In addition to the resistance mutations at amino acids 155, 156, and 168, there were 12 289 positions in the NS3 protease with amino acid changes at Day 4 and/or 14 (positions: 14, 290 18, 54, 72, 80, 86, 87, 91, 114, 147, 170 and 174) . Seven of these twelve substitutions 291 were observed with R155 or D168 mutants (Table 1, 
supplementary). Cross referencing 292
the amino acid substitutions at these residues against an amino acid frequency database of 293 938 NS3 protease amino acid sequences of GT 1a and 1b collected from the EU 294 databases revealed that these substitutions appear to be at highly polymorphic sites and 295 may therefore be natural variation (>1%) of the WT HCV population. Substitutions at 296 positions 80 and 147 that were observed as a mixtures of 2-4 amino acids (K/Q80I/K/L/Q 297 and A/S147A/L/S/V) do not appear to be associated with GS-9451 selection and most of 298 these amino acids are possible substitutions observed in WT HCV. One substitution at 299 position 170 (I170T) was changed to an amino acid observed with <1% frequency in the 300 databases (I170I/T, I=58%, T=0.1%, V=42%). This substitution was observed in only 301 one patient. Table 4 . Samples from GT 1a patients with full R155K mutants (patients 313 BE, BJ, CD and CF) had at least an increase in EC 50 of >595 fold to GS-9451 compared 314 to baseline (Table 4b) . As with replicon single mutants (Table 4a ), all patient isolates had 315 reduced replication capacities compared to the wild-type replicon. Both patient isolates 316 and replicon R155K showed high levels of resistance to Amino acid changes at position D168 were observed in four GT 1b patients. Patients with 318 full D168V (patient DH) and D168G (DD) were analyzed for their susceptibility to GS-319 9451. The Day 4 samples from both patients DH and DD displayed >152-fold reduced 320 susceptibility to GS-9451 as compared to their baseline samples (Table 4b ). Interestingly, 321 patient DH with full D168V displayed higher levels of resistance to GS-9451 compare to 322 patient DD with full D168G, which correlates with the resistance levels of the replicon 323 mutants (Table 4a) . 
Cross-resistance Analyses 326
It is anticipated that GS-9451 may be used in combination with PEG-IFN and RBV as 327 well as other DAAs in the future. Therefore, the susceptibilities of GS-9451 resistant 328 variants to other HCV inhibitors were determined using a transient replication assay. 329
Chimeric replicons carrying the NS3 protease gene from patients determined to carry 330 known PI resistant mutations together with their corresponding baseline samples were 331 used for cross-resistance analyses. Table 5 shows cross-resistance data from a set of 332 patient isolates harboring full mutations at positions 155 or 168 to represent the spectrum 333 of HCV mutants observed. Baseline isolates for all these patients (BE, BJ, CD, CF, DH 334 and DD) were sensitive to all nine HCV DAAs tested. Day 4 or Day 14 GT 1a patient 335
isolates with mutations at R155 in HCV protease displayed moderate to high levels of 336 resistance to the HCV PIs GS-9256, danoprevir and TMC-435, and low to moderate 337 levels to telaprevir and boceprevir. The D168V or D168G mutants displayed a high level 338 of resistance to the protease inhibitor GS-9256, however they were fully susceptible to 339 telaprevir and boceprevir. One GT 1b patient isolate (DH) with a full D168V mutation 340 displayed high levels of cross-resistance to TMC-435 (>174-fold). However, an isolate 341 with a full D168G mutation from patient DD was susceptible to TMC-435. All of these 342 GS-9451-resistant mutants were fully susceptible to the non-nucleoside polymerase 343 inhibitors GS-9190 and GS-9669, the nucleoside polymerase inhibitor GS-6620, the 344 NS5A inhibitor GS-5885, as well as IFN-α, and RBV, indicating no cross-resistance of 345 GS-9451 resistance mutations with these inhibitors (Table 5) . moderate to high levels to TMC-435 and danoprevir, and low to moderate levels to 363 telaprevir and boceprevir, in vitro. Interestingly, one patient isolate with a full D168V 364 mutation displayed high levels of cross-resistance to TMC-435 compare to another 365 patient isolate with a full D168G mutation. Our observations support previously reported 366 data that showed that D168V confer higher levels of resistance to TMC435 compare to 367 D168G (11). The D168 isolates were fully susceptible to telaprevir and boceprevir, 368 suggesting the option of treatment with these approved PIs for these patients. study by population sequencing after three days administration of GS-9451. In vitro 383 studies showed that T54A/S, V36M, and R155T are sensitive to GS-9451, while 384 mutations at A156 were cross-resistant to GS-9451 (data not shown). 385
Interestingly, no NS3 mutations were observed by population sequencing in patients who 386 received GS-9451 at 60 mg QD for three days. We observed that the emergence of 387 resistant variants in this study correlated with the degree of GS-9451 selective pressure, 388 higher dose, and greater HCV viral load reductions. This observation suggests that the 389 mutant viruses pre-exist at low levels prior to treatment, and once the WT population was 390 sufficiently inhibited by GS-9451, the resistant variants were detectable by population 391 sequencing. The levels of pre-existing mutations at baseline are too low to be detected by 392 The replication capacity of the R155K replicon was slightly lower than the D168 417 mutants, however, the backbone of the R155K (1a replicon) and D168 (1b replicon) 418 mutants were different. For all patient isolates the replication capacities were lower than 419 the 1b replicon which suggests incompatibility between the patient isolates and the 420 replicon subtype backbone or other accumulated mutations that affect RNA replication. 421
Interestingly, the replication capacities at Day 4 or 14 were comparable or lower than the 422 baseline of the same subject. That may also suggest that most of the virus populations at 423 these timepoints are mutants with lower replication capacities. 424
Previous in vitro replicon studies identified the A156T/G resistant mutant for GS-9451 425 (27). The reason that this variant was not detected in patients could be due to a lower 426 frequency of the pre-existing A156 mutants as compared to the R155K mutant in GT 1a 427 and D168 mutants in GT 1b at baseline and/or reduced fitness of the virus in patients. 428
Substitutions at positions 80 and 170 that previously were shown to confer resistance to 429 other PIs (11) were observed in only one patient for each substitution, and will be further 430
investigated. 431
Sequences of the C-terminal helicase domain of NS3 and the co-factor NS4A were also 432 analyzed for their change from baseline. Substitutions detected in this region appear to 433 be natural variations of the HCV WT population that are present at >1% in the EU 434 databases. In this study the GS-9451-associated resistant mutants all mapped to the NS3 435 protease domain. 1 Replication capacity relative to WT GT 1a or GT 1b replicon was determined as the 637 ratio of luciferase activity in untreated cells at 96 hr relative to the 4 hr input timepoint. 
